Two analysts have scored a 100% success rate on their recommendations for two companies: American multinational toy manufacturer Mattel, Inc. (NASDAQ:MAT) and clinical-stage pharma company Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX).
Wall Street analysts are known for their stock-picking prowess and in-depth knowledge of the companies and sectors under their coverage. Investors often follow analysts’ calls to make informed investment decisions. Let us look at both the companies and the analysts’ returns generated on them.
Mattel (NASDAQ:MAT)
Analyst Tami Zakaria of J.P. Morgan has given 10 ratings on Mattel stock to date, boasting a 100% success rate. Notably, all of Zakaria’s ratings on MAT have been a Buy since January 2020. Through her calls, the analyst has generated an impressive 44.93% average return per rating. This implies that had an investor followed Zakaria’s views on MAT stock, he or she would have earned 44.93% on average to date.
The chart below displays Zakaria’s consistent Buy recommendations for the Barbie and Hot Wheels manufacturing company. MAT stock has lost 9.1% year-to-date vis-à-vis gaining 3.7% over the past year.
Is MAT a Buy or Sell?
On TipRanks, Mattel has a Moderate Buy consensus rating. This is based on four Buys and two Holds. The average Mattel price forecast of $28.20 implies 42.6% upside potential to current levels.
Amylyx Pharmaceuticals (NASDAQ:AMLX)
Analyst Neena Bitritto-Garg of Citigroup has given a total of seven ratings on AMLX stock with a 100% success rate. Since May 2022, the analyst has given consistent Buy recommendations on Amylyx, generating a massive 103.05% average return per rating.
After learning that the Relyvrio drug had received full FDA approval for the treatment of the neurodegenerative disease amyotrophic lateral sclerosis (ALS), Bitritto-Garg raised the price target on AMLX to $50 from $48.
Is Amylyx Pharmaceuticals a Buy?
Amylyx Pharmaceuticals stock has a Moderate Buy consensus rating on TipRanks. This is based on two Buys versus one Hold. The average Amylyx Pharmaceuticals price target of $45 implies a reasonable 36.1% upside potential to current levels. Meanwhile, the stock has already shot up 83% so far this year.
Closing Thoughts
Both Bitritto-Garg and Zakaria have conducted thorough research on these companies and given their recommendations, giving them a 100% success rate. Following their calls may prove to be beneficial to your portfolio. Notably, TipRanks accumulates the recommendations of several Top Experts, which can be considered while making investment choices to maximize returns.
